Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The study will assess efficacy, safety and tolerability of 0.5 mg/day and 1 mg/day of
sublingual (under the tongue) formulation of agomelatine in patients with Major Depressive
Disorder. This study includes an 8-week double-blind phase.